These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 33941038

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
    Mayendraraj A, Rosenkilde MM, Gasbjerg LS.
    Peptides; 2022 May; 151():170749. PubMed ID: 35065096
    [Abstract] [Full Text] [Related]

  • 24. GLP-1R activation for the treatment of stroke: updating and future perspectives.
    Darsalia V, Nathanson D, Nyström T, Klein T, Sjöholm Å, Patrone C.
    Rev Endocr Metab Disord; 2014 Sep; 15(3):233-42. PubMed ID: 24777909
    [Abstract] [Full Text] [Related]

  • 25. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH.
    Curr Med Res Opin; 2016 Sep; 32(1):61-76. PubMed ID: 26439329
    [Abstract] [Full Text] [Related]

  • 26. Anti-Inflammatory Effects of GLP-1R Activation in the Retina.
    Puddu A, Maggi D.
    Int J Mol Sci; 2022 Oct 17; 23(20):. PubMed ID: 36293281
    [Abstract] [Full Text] [Related]

  • 27. Pancreatic alpha cells in diabetic rats express active GLP-1 receptor: Endosomal co-localization of GLP-1/GLP-1R complex functioning through intra-islet paracrine mechanism.
    Nakashima K, Kaneto H, Shimoda M, Kimura T, Kaku K.
    Sci Rep; 2018 Feb 27; 8(1):3725. PubMed ID: 29487355
    [Abstract] [Full Text] [Related]

  • 28. Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects.
    Hayes MR.
    Physiol Behav; 2012 Jun 06; 106(3):413-6. PubMed ID: 22366059
    [Abstract] [Full Text] [Related]

  • 29. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype.
    Flamez D, Gilon P, Moens K, Van Breusegem A, Delmeire D, Scrocchi LA, Henquin JC, Drucker DJ, Schuit F.
    Diabetes; 1999 Oct 06; 48(10):1979-86. PubMed ID: 10512362
    [Abstract] [Full Text] [Related]

  • 30. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
    Yamagishi S, Matsui T.
    Curr Pharm Des; 2011 Dec 06; 17(38):4379-85. PubMed ID: 22204436
    [Abstract] [Full Text] [Related]

  • 31. GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action.
    Lee SP, Qi J, Xu G, Rankin MM, Littrell J, Xu JZ, Bakaj I, Pocai A.
    Front Endocrinol (Lausanne); 2021 Dec 06; 12():652628. PubMed ID: 34054727
    [Abstract] [Full Text] [Related]

  • 32. Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.
    Muscogiuri G, DeFronzo RA, Gastaldelli A, Holst JJ.
    Trends Endocrinol Metab; 2017 Feb 06; 28(2):88-103. PubMed ID: 27871675
    [Abstract] [Full Text] [Related]

  • 33. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1.
    Hayes MR, Kanoski SE, De Jonghe BC, Leichner TM, Alhadeff AL, Fortin SM, Arnold M, Langhans W, Grill HJ.
    Am J Physiol Regul Integr Comp Physiol; 2011 Nov 06; 301(5):R1479-85. PubMed ID: 21849636
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Expression of glucagon-like peptide-1 (GLP-1) receptor and the effect of GLP-1-(7-36) amide on insulin release by pancreatic islets during rat ontogenic development.
    García-Flores M, Zueco JA, Alvarez E, Blázquez E.
    Eur J Biochem; 2001 Feb 06; 268(3):514-20. PubMed ID: 11168389
    [Abstract] [Full Text] [Related]

  • 37. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.
    Zhao F, Zhou Q, Cong Z, Hang K, Zou X, Zhang C, Chen Y, Dai A, Liang A, Ming Q, Wang M, Chen LN, Xu P, Chang R, Feng W, Xia T, Zhang Y, Wu B, Yang D, Zhao L, Xu HE, Wang MW.
    Nat Commun; 2022 Feb 25; 13(1):1057. PubMed ID: 35217653
    [Abstract] [Full Text] [Related]

  • 38. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease.
    Perry T, Greig NH.
    Curr Alzheimer Res; 2005 Jul 25; 2(3):377-85. PubMed ID: 15974903
    [Abstract] [Full Text] [Related]

  • 39. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.
    McKay NJ, Kanoski SE, Hayes MR, Daniels D.
    Am J Physiol Regul Integr Comp Physiol; 2011 Dec 25; 301(6):R1755-64. PubMed ID: 21975647
    [Abstract] [Full Text] [Related]

  • 40. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT, Kieffer TJ.
    Minerva Endocrinol; 2002 Jun 25; 27(2):79-93. PubMed ID: 11961501
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.